Skip to content

CCT for Older Diabetic Adults

The Effects of Computerized Cognitive Training on Diabetic Elderly, Who Are at High Risk for Dementia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02709629
Enrollment
85
Registered
2016-03-16
Start date
2015-08-31
Completion date
2017-12-31
Last updated
2018-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Older Diabetic Persons Without Dementia

Brief summary

The current study examines the efficiency of a home-based computerized cognitive training (CT) intervention targeting older adults with diabetes.The primary aim of the study is to evaluate the effects of CCT on cognitive and disease management in non-demented older diabetes adults. Investigators will also evaluate the effect of the intervention on a range of secondary outcomes, including mood, caregiver burden, self-efficacy, and for a small sub-sample, on brain activity as reflected in changes in task-related blood-flow on fMRI.

Detailed description

Evidence suggests a link between diabetes-related processes and increased risk of cognitive decline and dementia in older adults. Optimal disease self-management may be key in the prevention of cognitive decline among older diabetic patients, but this may be compromised due to sub-clinical cognitive impairment. In the current study, 120 community-dwelling, non-demented participants aged 65 and over, with a diagnosis of Type 2 diabetes will be randomly assigned either to an 8-week, home-based individually-tailored CCT program with adaptive difficulty level, and regular performance feedback, or to an 8-week, home-based active control (AC) condition, involving training on a generic CCT program with fixed difficulty level and without performance feedback. Both intervention groups also include a range of theory-informed behavior change techniques (BCTs), including self-efficacy management, self-monitoring and goal-setting in order to enhance treatment fidelity, and to maximize treatment compliance and adherence. In both groups, participants train approx. 30 min. per day, 3 times per-week for 8-weeks. Participants undergo a comprehensive evaluation of all outcomes at baseline, immediately after the intervention, and at a 6-month follow-up, with 1-week booster training completed 3 months from completion of the intervention.

Interventions

BEHAVIORALIndividualized and adaptive computerized cognitive training
BEHAVIORALActive control

Sponsors

Maccabi Healthcare Services, Israel
CollaboratorOTHER
Sheba Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 65 and over * diagnosis of type 2 diabetes * Health cover provided by Maccabi Health Services (MHS) * Access to a home computer and internet connection * Availability of a close relative/informant with regular and frequent contact with the participant (at least 10 hours per week), willing to respond to questionnaires at all time points. * Fluency in Hebrew or English * Living in the Tel-Aviv metropolitan area and surrounds

Exclusion criteria

* An existing diagnosis of dementia * Prescription of dementia-related medication. * Participation in a previous cognitive intervention study in the preceding year. * Significant hearing/vision impairment likely to interfere with assessment and/or training * Significant psychiatric/neurological or medical issues that may affect cognitive function.

Design outcomes

Primary

MeasureTime frame
Change from baseline in global cognition as reflected in a composite cognitive score at 9 weeks9 weeks
Change from baseline in diabetes self management as reflected in the diabetes self-management questionnaire9 weeks

Secondary

MeasureTime frame
Change in domain-specific cognitive abilities (memory, non-memory) measured by composite scores from the neuropsychological test battery, at 35 weeks35 weeks (6 months follow up)
Change in meta-memory (subjective ratings of memory performance), as reflect on the Meta-Memory Questionnaire, at 35 weeks35 weeks (6 months follow up)
Change in self-reported mood-related symptoms on the geriatric depression scale at 9 weeks9 weeks
Change in self-reported mood-related symptoms on the geriatric depression scale at 35 weeks35 weeks (6 months follow up)
Change in meta-memory (subjective ratings of memory performance) as reflect on the Meta-Memory Questionnaire at 9 weeks9 weeks
Change in informant-reported care-giving burden on the Zarit Burden Interview at 35 weeks35 weeks (6 months follow up)
Change in blood sugar levels on a blood glucose test at 35 weeks35 weeks
Change from baseline in global cognition as reflected in a composite cognitive score at 35 weeks35 weeks
Change from baseline in diabetes self-management as reflected in scores on the diabetes self-management questionnaire at 35 weeks35 weeks
Change in informant-reported care-giving burden on the Zarit Burden Interview at 9 weeks9 weeks
Change in domain-specific cognitive abilities (memory, non-memory) measured by composite scores from the neuropsychological test battery, at 9 weeks9 weeks(immediately post-intervention)

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026